Journal Article DKFZ-2020-03050

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Treatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy - results from a large multicenter analysis.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2021
Elsevier Science Amsterdam [u.a.]

Radiotherapy and oncology 156, 266-274 () [10.1016/j.radonc.2020.12.024]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: To evaluate oncological outcomes and treatment-related toxicities of elderly salivary gland cancer patients undergoing (chemo)radiotherapy.Local/locoregional control (LRC), progression-free survival (PFS) and overall survival (OS) of elderly patients ≥65 years with primary salivary gland cancers undergoing (chemo)radiotherapy between 2005 and 2020 at three tertiary cancer centers were calculated. The impact of clinicopathological and treatment parameters on outcomes were analyzed, and acute and chronic toxicities were quantified.288 elderly salivary gland cancer patients were included in this multicenter analysis, and their median LRC, PFS and OS amounted to 113, 39 and 75 months, respectively. Age, performance status, comorbidities, definitive vs. adjuvant (chemo)radiotherapy as well as locally/locoregionally advanced cancers and distant metastases correlated with reduced outcomes in elderly salivary gland patients. Patients receiving dose-escalated radiotherapy (total doses >70 GyEQD2) with carbon ion boost radiation resulted in improved LRC, but no improvements in PFS or OS. Concomitant chemoradiotherapy did not improve treatment outcomes in elderly salivary gland carcinoma patients. Radiotherapy of elderly salivary gland cancer patients resulted in moderate higher-grade toxicities despite dose escalation with 70 (24.3%) and 48 patients (16.7%) experiencing acute and chronic grade 3 toxicities, respectively. No grade 4/5 toxicities were observed in this patient cohort.Data from the largest multicenter analysis of elderly salivary gland cancer patients undergoing (chemo)radiotherapy demonstrate favorable LRC and tolerable toxicity rates. Decision-making for these vulnerable patients should be based on patient performance rather than chronological patient age.

Keyword(s): Chemotherapy ; Elderly patients ; Geriatric patients ; Head-and-neck cancer ; Radiotherapy ; Salivary gland cancer

Classification:

Note: Volume 156, March 2021, Pages 266-274 / #LA:E055#

Contributing Institute(s):
  1. DKTK FM zentral (FM01)
  2. DKTK FR zentral (FR01)
  3. DKTK HD zentral (HD01)
  4. E050 KKE Strahlentherapie (E050)
  5. E055 KKE Molekulare Radioonkologie (E055)
Research Program(s):
  1. 315 - Bildgebung und Radioonkologie (POF4-315) (POF4-315)

Appears in the scientific report 2021
Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2020-12-30, last modified 2024-02-29



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)